EUCTR2018-004076-35-ESActive, not recruitingPhase 1
A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Incyte Corporation
- Enrollment
- 98
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Ability to comprehend and willingness to sign a written ICF for the study.
- •2. Men or women aged 18 years or older.
- •3. Prior diagnosis of MM according to IMWG diagnostic criteria.
- •4. Has measurable disease at screening, as defined by the following:
- •Serum M-protein level = 1.0 g/dL, or
- •Urine M-protein level = 200 mg/24 hours, or
- •Serum Ig FLC = 10 mg/dL and abnormal serum Ig kappa to lambda FLC ratio.
- •5. Has received at least 3 prior lines (including PI, IMiD, and anti-CD38 therapies) but not more than 5 prior lines of MM treatment.
- •a. Has received last dose of prior anti-CD38 therapy at least 3 months before initiation of study treatment.
- •b. Has achieved a response (MR or better), based on investigator’s evaluation of response by IMWG criteria, to prior anti-CD38 therapy.
- •c. Has documented evidence of PD as defined by the IMWG criteria on or after their last regimen.
- •6. ECOG performance status of 0 or 1.
- •7. Willing to avoid pregnancy or fathering children based on the criteria below:
- •a. Woman of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR = 12 months of amenorrhea and at least 51 years of age).
- •b. Woman of childbearing potential who has a negative serum pregnancy test at screening and before the first dose on Day 1 and who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening until 3 months after the last dose of the last component of study treatment and must refrain from donating eggs (ova, oocytes). Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participant and their understanding confirmed.
- •c. Man who agrees to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening until 3 months after the last dose of the last component of study treatment and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participant and their understanding confirmed.
- •8. Willing to provide fresh and archival bone marrow aspiration and biopsy tissue during screening and on study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 78
Exclusion Criteria
- •1. Receipt of any of the following treatment within the indicated interval before the first administration of study drug:
- •a. Anti-myeloma treatment within 2 weeks or 5 half-lives (whichever is longer).
- •- Exception: Washout of immune checkpoint inhibitor therapy is NOT required.
- •b. Investigational drug (including investigational vaccines) or invasive investigational medical device within 4 weeks.
- •c. Autologous stem cell transplant within 12 weeks, or allogeneic stem cell transplant at any time.
- •d. Plasmapheresis within 4 weeks.
- •e. Radiation therapy within 2 weeks.
- •f. Major surgery within 2 weeks, or inadequate recovery from an earlier surgery, or surgery planned during the time the participant is expected to participate in the study or within 2 weeks after the last dose of study treatment.
- •2. Toxicity = Grade 2 from previous anti-myeloma therapy except for stable chronic toxicities (= Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.
- •3. Known additional malignancy (other than MM) that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent.
- •4. Known meningeal involvement of MM.
- •5. Participants with laboratory values at screening defined in the protocol (Table 10).
- •6. Significant concurrent, uncontrolled medical condition, including but not limited to the following:
- •a. Known COPD (defined as a FEV1 < 50% of predicted normal), persistent asthma, or history of asthma within the past 2 years. Participants with known or suspected COPD or asthma must have a FEV1 test during screening.
- •b. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
- •c. Acute diffuse infiltrative pulmonary disease.
- •d. Clinically significant or uncontrolled cardiac disease, including the following:
- •- Unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy unless approved by medical monitor.
- •- History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful. A screening QTcF interval > 470 ms is excluded.
- •e. Inability of the participant to swallow and retain oral medication.
- •7. Any of the following:
- •a. Known to be seropositive for hepatitis B (defined by a positive test for HBsAg). Participants with resolved infection (ie, participants who are HBsAg-negative but positive for antibodies to anti-HBc and/or anti-HBs) must be screened using real-time PCR measurement of HBV DNA levels. Those who are PCR-positive will be excluded.
- •- Exception: Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.
- •b. Known to be seropositive for hepatitis C. Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at screening visit.
- •c. Known to be seropositive for HIV. HIV testing is not required unless mandated by the local health authority.
- •8. Plasma cell leuke
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersAnaemia associated with myelofibrosis whether as a de novo disorder (PMF) or evolve secondarily from previous PV or ET (post–PV MF or post–ET MF).MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004029-21-ITINCYTE CORPORATIO100
Recruiting
Phase 1
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersAnemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera MyelofibrosisJPRN-jRCT2031210445eda Eiji100
Recruiting
Phase 2
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders2023-503624-83-00Incyte Corp.90
Active, not recruiting
Phase 1
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple MyelomaParticipants who are transfusion-dependent or present with symptomatic anemiafor MDS participants who are ineligible to receive or have not responded to available therapies for anemia and for MM after failure of available standard treatments.MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2020-002771-35-FRIncyte Corporation80
Active, not recruiting
Phase 1
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple MyelomaParticipants who are transfusion-dependent or present with symptomatic anemiafor MDS participants who are ineligible to receive or have not responded to available therapies for anemia and for MM after failure of available standard treatments.MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2020-002771-35-ITINCYTE CORPORATIO80